Role of Haloperidol in Palliative Medicine: An Update

Eric Prommer

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia. Awareness of the role dopamine plays in many symptoms in palliative care, such as nausea, vomiting, and delirium, has led to the use of dopamine antagonists such as haloperidol for the treatment of these symptoms in the palliative care setting. Listed as 1 of the 25 important drugs in palliative care, haloperidol can be administered by multiple routes and can be given without dose alteration in the setting of both renal and hepatic insufficiency. Haloperidol is extensively metabolized in the liver, with CYP3A4 the chief cytochrome oxidase responsible for metabolism. This article will review the pharmacology, pharmacokinetics, and current uses of haloperidol in palliative medicine. There will be an examination of the evidence base for the use of haloperidol in palliative medicine.

Original languageEnglish (US)
Pages (from-to)295-301
Number of pages7
JournalAmerican Journal of Hospice and Palliative Medicine
Volume29
Issue number4
DOIs
StatePublished - 2012

Fingerprint

Haloperidol
Palliative Care
Dopamine Antagonists
Butyrophenones
Hepatic Insufficiency
Cytochrome P-450 CYP3A
Delirium
Electron Transport Complex IV
Nausea
Antipsychotic Agents
Vomiting
Renal Insufficiency
Palliative Medicine
Dopamine
Schizophrenia
Pharmacokinetics
Pharmacology
Liver
Therapeutics
Pharmaceutical Preparations

Keywords

  • delirium
  • dopamine
  • dosing
  • haloperidol
  • nausea
  • QT interval

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Role of Haloperidol in Palliative Medicine : An Update. / Prommer, Eric.

In: American Journal of Hospice and Palliative Medicine, Vol. 29, No. 4, 2012, p. 295-301.

Research output: Contribution to journalArticle

@article{9461e31f0276467fb71da3825957c274,
title = "Role of Haloperidol in Palliative Medicine: An Update",
abstract = "Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia. Awareness of the role dopamine plays in many symptoms in palliative care, such as nausea, vomiting, and delirium, has led to the use of dopamine antagonists such as haloperidol for the treatment of these symptoms in the palliative care setting. Listed as 1 of the 25 important drugs in palliative care, haloperidol can be administered by multiple routes and can be given without dose alteration in the setting of both renal and hepatic insufficiency. Haloperidol is extensively metabolized in the liver, with CYP3A4 the chief cytochrome oxidase responsible for metabolism. This article will review the pharmacology, pharmacokinetics, and current uses of haloperidol in palliative medicine. There will be an examination of the evidence base for the use of haloperidol in palliative medicine.",
keywords = "delirium, dopamine, dosing, haloperidol, nausea, QT interval",
author = "Eric Prommer",
year = "2012",
doi = "10.1177/1049909111423094",
language = "English (US)",
volume = "29",
pages = "295--301",
journal = "American Journal of Hospice and Palliative Medicine",
issn = "1049-9091",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Role of Haloperidol in Palliative Medicine

T2 - An Update

AU - Prommer, Eric

PY - 2012

Y1 - 2012

N2 - Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia. Awareness of the role dopamine plays in many symptoms in palliative care, such as nausea, vomiting, and delirium, has led to the use of dopamine antagonists such as haloperidol for the treatment of these symptoms in the palliative care setting. Listed as 1 of the 25 important drugs in palliative care, haloperidol can be administered by multiple routes and can be given without dose alteration in the setting of both renal and hepatic insufficiency. Haloperidol is extensively metabolized in the liver, with CYP3A4 the chief cytochrome oxidase responsible for metabolism. This article will review the pharmacology, pharmacokinetics, and current uses of haloperidol in palliative medicine. There will be an examination of the evidence base for the use of haloperidol in palliative medicine.

AB - Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia. Awareness of the role dopamine plays in many symptoms in palliative care, such as nausea, vomiting, and delirium, has led to the use of dopamine antagonists such as haloperidol for the treatment of these symptoms in the palliative care setting. Listed as 1 of the 25 important drugs in palliative care, haloperidol can be administered by multiple routes and can be given without dose alteration in the setting of both renal and hepatic insufficiency. Haloperidol is extensively metabolized in the liver, with CYP3A4 the chief cytochrome oxidase responsible for metabolism. This article will review the pharmacology, pharmacokinetics, and current uses of haloperidol in palliative medicine. There will be an examination of the evidence base for the use of haloperidol in palliative medicine.

KW - delirium

KW - dopamine

KW - dosing

KW - haloperidol

KW - nausea

KW - QT interval

UR - http://www.scopus.com/inward/record.url?scp=84865497434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865497434&partnerID=8YFLogxK

U2 - 10.1177/1049909111423094

DO - 10.1177/1049909111423094

M3 - Article

C2 - 21998445

AN - SCOPUS:84865497434

VL - 29

SP - 295

EP - 301

JO - American Journal of Hospice and Palliative Medicine

JF - American Journal of Hospice and Palliative Medicine

SN - 1049-9091

IS - 4

ER -